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Abstrati-Demographic and survival data are presented for 390 patients with scleroderma. For the 
entire group qn estimated.ll.rl% survived 5 years from diagnosis and 69.4% survived 10 years. 
Life-table analyses revealed that adequate treatment with potassium para-aminobenzoate (Potaba@ 
KPAB) was associated with improved survival (p c 0.01); 88.5% 5 year survival rate and 76.6% 
10 year survival rate for adequately treated patients. Five and ten year survival rates for patients 
never treated with KPAB were 69.8 and 56.6%, respectively. Similar findings were obtained by 
comparing observed to expected mortality for these patients; ag+in, KPAB therapy showed 
prolongation of survival. The Cox proportional hazards model was also applied to this retro- 
spective study adjusting for baseline clinical involvement, demographics and KPAB treatment. 
There were some interesting results including a high sign&ance for skin involvement per se as a 
prognostic indicator: the greater the extent of skin involvement the poorer prognosis. Tiie from 




Retrospective study Potassium para-aminobenzoate therapy Improved 
INTRODUCTION 
The purpose of this report is to present survival 
data for a group of 390 patients with sclero- 
derma who had been seen at The University of 
Michigan Medical Center during the period 
1948 to July 1980. In the initial paper of this 
series [l] the patient population of this retro- 
spective study was characterized, and the soft- 
ening effect of therapy with potassium para- 
aminobenzoate (Potabam, KPAB) on 
sclerodermatous skin was confirmed. One of the 
main objectives of the analyses herein reported 
is to examine whether there were differences in 
survival consequent to treatment or non- 
treatment with potassium para-aminobenzoate. 
In addition, analyses were performed to deter- 
mine whether survival was affected by duration 
of the disease at the time of entry into the study, 
Requests for reprints should be addressed to: Chris J. D. 
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and for possible prognostic significance of 
specified clinical findings at time of entry. Re- 
sults of these analyses form the basis of this 
report. 
MATERIALS AND MRTHODS 
The method8 used to identify and characterize 
this population of 390 scleroderma patients 
were detailed in the initial report of this series 
[l]. Data were extracted according to protocol 
for each clinic visit or admission to the Univer- 
sity of Michigan hospital. The protocol listed 
479 variables for which entries could be coded. 
Follow-up information was augmented by ex- 
tensive correspondence and telephone contact. 
These patients came from widely scattered areas 
with most from Michigan, Ohio, Indiana, Illi- 
nois and Pennsylvania. Patients were generally 
referred by outside physicians to the De- 
partment of Internal Medicine and/or its 
sub-specialty sections of Rhvatology or 
Hematology (Simpson Memorial Institute, to 
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the Department of Dermatology, or to the 
Department of Pediatrics. 
All patients satisfied at entry the diagnostic 
criteria for systemic scleroderma. Patients with 
scleroderma plus aspects of “mixed connective 
tissue disease”, lupus erythematosus, dermato- 
myositis, etc. were excluded from this analysis, 
however, since these associated manifestations 
would complicate interpretation of subsequent 
organic changes that might also be attributable 
to scleroderma. The group of 390 patients with 
scleroderma alone made 3746 coded visits (in- 
cluding admissions) to the University Hospital, 
an average of 9.6 per patient. These patients 
were followed from diagnosis for a total of 
3394.6 years, an average of 8.71 years per 
patient. There were 208 patients with recorded 
visits (either an actual visit or a record entry 
indicating the patient’s death status had been 
ascertained through the follow-up procedure) 
after 31 December 1978. Only 40 patients were 
lost to follow-up prior to that date. Among the 
latter, loss of four occurred during the period 
1951-1956, another 20 were lost during 
1962-1972, and 16 were lost with the last con- 
tact at sometime during 1973-1978. Accretion 
of study data was continued for all patient visits 
or admissions to July 1980. 
From the follow-up procedures it was deter- 
mined that 142 of the 390 patients had died 
before the end of the study, leaving 208 patients 
that were alive or lost to follow-up. The survival 
times for all patients were determined as fol- 
lows: for those 142 patients who died, the 
survival time was the elapsed time in years 
between the “entry date” and the date of death. 
The remaining 248 patients, for purposes of this 
analysis, were considered lost to follow-up on 
the date of the last recorded visit to University 
Hospital. All of the analyses were performed 
without regard to specific cause of death, treat- 
ing all deaths as scleroderma deaths. 
Because this is a retrospective analysis, 
several definitions of date of entry were used to 
insure that any potential biases associated with 
a particular definition of survival were evalu- 
ated. Alternative definitions of “date of entry” 
include date of first diagnosis, date of first 
symptom, date of first University of Michigan 
Hospital visit, and date of initial complete med- 
ical evaluation at University Hospital. 
*The computer software package BMDP [9] was used to 
generate the life tables and to perform the Cox analyses 
and all the associated statistical tests. 
For the purpose of describing the survival 
data for this patient population, the date of 
initial diagnosis of scleroderma was taken as the 
date of entry. This designation also permits 
comparison of findings to those of a number of 
other studies which performed survival analyses 
based on date of scleroderma diagnosis [2-51. 
Date of diagnosis was not necessarily the date 
of the first University of Michigan Hospital 
visit, rather it was the first physician diagnosis 
of scleroderma. The earliest date was June 1946, 
the mean date was 1968, and average age at 
diagnosis was 42.4 years. 
The survival times were analyzed using 
several methodologies. First, the survival data 
were analyzed using the life-table method. Sur- 
vival curves were plotted using the 
Kaplan-Meier method [6]. Differences between 
the estimated survival curves for the population 
subgroups were evaluated using the 
Mantel-Cox test [7]. p-Values are reported for 
two tailed significance levels. 
Within the context of the life-table analyses it 
was also informative to compare the observed 
mortality of our patient population to the ex- 
pected mortality for the same patients using age 
(at diagnosis), race, and sex specific U.S. death 
rates. 
Finally, the Cox proportional-hazards model 
[8] was used to analyze the data.* This was done 
because differences in survival between two sub- 
groups cannot necessarily be attributed to the 
particular characteristic distinguishing the two 
groups when other factors that affect survival 
differ between the groups being tested. The 
life-table method and the associated statistics 
for testing equality among survival curves as- 
sume that the subgroups being tested are ho- 
mogeneous with respect to all other factors 
affecting survival. The Cox proportional- 
hazards model permits evaluation of the 
separate effects of multiple demographic and 
prognostic factors and simultaneously accounts 
for heterogeneity of subgroups. Moreover, the 
Cox model provides a stronger test for evalu- 
ating the effects of treatment on survival be- 
cause it allows the statistical comparison of 
treated and non-treated groups while correcting 
for differences in demographic characteristics 
and important associated organ system in- 
volvements that are present at the outset of 
treatment. 
With these points in mind, seven indicators of 
health status or organ system involvement at 
date of entry were used in addition to age, sex, 
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race, and KPAB treatment category as covar- 
iates in Cox analyses. Among the clinical ele- 
ments chosen for analysis with regard to their 
prognostic potential were: (1) the extent of skin 
involvement [categorized as to (a) minimal- 
mild, (b) moderate, or (c) marked or severe 
involvement] (1); (2) hypertension (documented 
history, systolic > 150 mmHg, or diastolic > 
90mmHg); (3) renal involvement (BUN > 
25.0 mg % or serum creatinine > 1.5 mg %); 
(4) pulmonary fibrosis by chest roentgenogram; 
(5) cardiac involvement (abnormal electro- 
cardiagram, pericardial effusion, or congestive 
failure by chest roentgenogram); (6) presence or 
history of characteristic Raynaud’s phenom- 
enon; and (7) esophageal involvement (dys- 
phagia and/or findings associated with sclero- 
derma on barium swallow or manometrics). 
Correlations among the covariates were evalu- 
ated using the (X-square test for independence 
in a contingency table. 
Statistical differences between models con- 
taining different covariates and significance of 
covariates within a model were evaluated using 
a likelihood ratio test distributed Chi square. In 
addition, the relative powers of the prognostic 
indicators were evaluated using a stepwise Cox 
methodology. 
RESULTS 
The survival data for this patient population 
by race, sex, and treatment group are sum- 
marized in Table 1. The average age at first 
diagnosis was 42.4 years while the average age 
at death was 54.5 years. In addition to being 
diagnosed at a younger age, Table 1 shows 
non-white patients dying younger on average 
than white. 
The ratio of females to male patients is 4.4; 
thus, females accounted for 81% of the total 
population. The mean age at entry for males 
and females was 42.0 and 42.4, respectively. 
Non-whites accounted for 12% of the 390 and 
were on average 6 years younger than whites at 
first diagnosis, 37.1 compared to 43.1 for whites. 
The mode of the age distributions occurred in 
the 4049 range for all race and sex subgroups. 
The treated patients are divided into those 
adequately and inadequately treated. Patients 
who took potassium para-aminobenzoate as 
prescribed for dose and duration were consid- 
ered “adequately treated” [l]. The usual daily 
dose was 12 g (four doses, 3 g each at meals and 
bedtime) or 12.5g (five doses, 2.5g each at 
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meals, mid-afternoon, and bedtime). In a few 
instances 10 g or less per day was prescribed for 
patients who weighed less than 100 lb. Patients 
who, for whatever reason, took less medication 
than was prescribed or discontinued treatment 
on their own after a brief interval were consid- 
ered to be “inadequately treated” with this 
medication. Duration of treatment was 
influenced by extent and severity of skin in- 
volvement and/or the presence of pulmonary 
fibrosis. When treatment with KPAB was ini- 
tiated, it was begun on average 2.4 years after 
the diagnosis of scleroderma had been made. At 
the above prescribed doses the beginning of skin 
softening may be detected clinically in some 
patients after about 3 months of treatment, with 
further softening at 6 months and beyond. 
Softening is very gradual. Treatment, therefore, 
has generally been continued as long as there 
was potential for further skin softening and/or 
significant pulmonary involvement was present. 
Thus, adequately treated patients took KPAB 
for periods ranging from 3 months to as long as 
20 years, with the average duration at 4.2 years. 
Treated patients accounted for 274 of the 
study population, and of these 219 were ade- 
quately treated. There were 116 patients who 
were at no time treated with KPAB. Mean age 
at diagnosis for the never treated group (44.1 
years) was 3.9 years older than the adequately 
treated group (40.2 years) and 3 years younger 
than the inadequately treated group. Of the 
never treated patients 39% died during the 
study period compared to 33 and 44% for the 
adequately and inadequately treated groups, 
respectively. Adequately treated patients died 
on average 1.6 years younger than the never 
treated with KPAB patients (53.1 vs 54.7 years). 
The last two columns of Table 1 compare the 
observed mortality of these patients to the ex- 
pected mortality based on standard U.S. 
age-race-sex specific death rates. The ratio of 
observed and expected deaths indicates that 
overall our study population experienced 5.4 
times the number of deaths expected the same 
standard U.S. population. Non-white males 
show the highest ratio, 8.84, while white males 
have the lowest, 4.40. The excess mortality 
rate in the last column is defined as 
[(observed - expected deaths)/person years at 
risk x lOOO], and indicates the rate of mor- 
tality relative to the expected rate. While 
substantially more females tend to develop 
scleroderma, Table 1 shows that males and 
particularly non-white males have higher death 
rates. The data by treatment group show the 
highest values for the ratio of observed to 
expected deaths (9.13) and for excess mortality 
(58.26) occur in the never treated group, while 
the adequately treated group has the lowest 
values (4.09 and 23.8). 
Life table survival results: demographics 
For the life-table analyses date of entry into 
the survival study was defined as date of initial 
diagnosis of scleroderma. A similar analysis was 
performed using the date of first symptom as 
reported by the patient. As would be expected, 
the survival times are longer when using the date 
of first symptom as the date of entry. However, 
only the results using date of first diagnosis as 
date of entry are reported here as the basic 
conclusions from the analyses were not altered. 
Table 2 summarizes the life-table analysis by 
age, sex, and race. 
Figure 1 shows the observed survival com- 
pared to the expected survival for all 390 pa- 
tients in our study. Scleroderma patients exhibit 
decreased survivorship compared to the stan- 
dard mortality of the U.S. population adjusted 
for the same demographic characteristics. The 
observed 5 year cumulative survival rate was 
81.4% and the 10 year rate was 69.4% 
(Table 2). 
As the scleroderma survival literature has 
indicated, age at entry is an important deter- 
minant of survival. The life-table analysis of 
survival by age confirms previous findings. 
Table 2 also compares survival of patients 40 
years of age and older at first diagnosis to that 
of patients under 40. The older patients have 
significantly decreased survivorship (Table 2, 
p < 0.001) compared to their younger counter- 
parts. This was to be expected since older 
patients naturally have higher mortality rates 
than younger ones. 
One method to adjust effectively for the “nat- 
ural” effects of age on survival is to compare 
excess mortality rates because expected mor- 
tality incorporates natural aging effects. If the 
disease did not have a differential impact by age 
then the excess mortality rate would not vary 
across age groups. However, the excess mor- 
tality rate for patients diagnosed after age 40 is 
43.56 while the rate for those diagnosed before 
age 40 is 18.02. The disease impact on the older 
group, adjusting for natural aging effects, is thus 
much more severe. Together the analyses indi- 
cate that age contributes to a generally poor 
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Table 2. Survival from first diagnosis* 
Test for 
differences 
Five- Seven- between groups 
Ten-year 
Number szal suy~ktl survival Mantel-Cox test 
at entry rate rate rate (p-value) 
Overall 390 81.4 77.1 69.4 
(2.1) (2.3) (2.7) - 
Female 318 84.2 79.8 72.7 
(2.2) (2.5) (2.9) 
0.057 
Male 72 69.2 65.0 54.6 
(5.8) (6.1) (7.1) 
White 342 82.4 78.0 70.7 
(2.2) (2.4) (2.8) 
0.154 
Non-white 48 74.4 70.9 59.0 
(6.7) (7.2) (9.7) 
Age at first diagnosis > 40 240 77.2 73.0 64.0 
(2.9) (3.1) (3.6) 
<O.OOl 
Age at first diagnosis < 40 150 87.8 83.2 77.8 
(2.8) (3.3) (3.9) 
*Standard errors in parentheses. 
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prognosis in addition to its natural mortality 
effects. 
Gender has also been shown to be an im- 
portant determinant of survival (Table 2). 
MaIes show an unfavorable prognosis relative 
to females but the difference failed to attain 
statistical significance (p = 0.057) at the 5% 
level. There was no significant difference be- 
tween the mean age at entry for these two 
groups. 
Although non-white patients had decreased 
survivorship compared to whites the difference 
was also not significant (p = 0.15) (Table 2). 
Life table survival results: e#ect of potassium 
para-aminobenzoate therapy 
These analyses provide strong evidence of the 
efficacy of KPAB therapy on the survival of 
i 4 
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Fig. 1. Survival curves, observed vs expected for 390 sclero- 
derma patients. A, Observed, x, Expected. 
patients with progressive systemic sclerosis. In 
this section the survival curves for the various 
treatment groups are examined, while in the 
next section the Cox model will provide a more 
powerful analytical tool which permits a more 
comprehensive comparison of treatment groups 
while adjusting for differences between groups 
for other factors known to affect survival. Table 
3 gives the 5,7, and IO-year cumulative survival 
rates for the 116 patients who were never treated 
with KPAB, and for the 274 patients who 
received KPAB at some time during their sclero- 
derma course. Those treated with KPAB have a 
significantly (p < 0.01) prolonged life span 
compared to the group who were never treated 
with KPAB. The treated group shows 5-year 
and lo-year survival rates of 85.7 and 73.9%, 
respectively, compared to 69.8 and 56.6% for 
the group that had never been treated with 
KPAB. 
If the treated group is divided into those 
adequately and inadequately treated, and the 
estimated survival curve of the adequately 
treated group is then compared to that of 
patients who had not received KPAB, the 
difference is even more pronounced. Figure 2 
shows the estimated survival curves for the 
adequately and never treated groups. The ade- 
quately treated group has significantly pro- 
longed survivorship (p < 0.01) with 5-year and 
IO-year cumulative survivor rates of 88.5 and 
76.7%, respectively. 
The importance of adequate treatment with 
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Table 3. Survival from first diagnosis* as related to KPAB treatment 
category 
Five- Seven- 
Number year year Ten-year 
at entry survival survival survival 
Treated with KPAB 274 85.7 81.5 73.9 
(2.2) (2.51 (3.01 
Adequately treated 219 88.5 84.5 76.7 
(2.21 (2.61 (3.2) 
Inadequately treated 55 74.0 68.6 61.9 
(6.3) (6.9) (7.7) 
Never treated 116 69.8 64.6 56.6 
(4.81 (5.3) (6.0) 
*Standard errors in parentheses. 
KPAB is evidenced by comparison of the inad- 
equately treated group to both the adequately 
and never treated groups. Testing the difference 
in these estimated survival curves shows a 
significant difference (p < 0.01) between the ad- 
equately and inadequately treated groups and 
no difference (p = 0.91) between the inade- 
quately and never treated with KPAB groups. 
These treatment groups differ with respect to 
other factors affecting survival. For example, 
the mean age of entry for the never treated 
group was 2.2 years older (44.1 vs 41.9) than the 
group who received KPAB treatment at some 
time, but this difference in mean ages was not 
significant (p = 0.18). For the adequately 
treated group the mean age of entry was 40.2 
and the 3.9 years age difference between the 
groups was significant (p = 0.04). The Cox 
analysis, discussed below, is applied to correct 
for differences in age as well as for other patient 
characteristics including sex, race, and health 
status. Before addressing the results of the Cox 
model analyses it is relevant to note that the 
effects of age can be controlled by examining the 
observed to expected mortality since the ex- 
Fig. 2. Survival curves for 335 scleroderma patients by 
KPAB treatment group: 219 treated adequately with KPAB 
vs 116 patients who never received KPAB. A, Never TX; 
x , Adequate TX. 
i. 
petted mortality rates embody the natural mor- 
tality effects of aging. The ratio of observed to 
expected deaths for the adequately, inade- 
quately, and never treated groups is 4.09, 6.88, 
and 9.13, respectively (Table 1). The excess 
mortality rates for the treatment groups have 
the same increasing pattern (23.8, 52.5, and 
58.26) with the never treated group having the 
highest rate and the adequately treated patients 
having the lowest. 
This pattern of relative mortality and the 
Mantel-Cox tests for differences in survival 
among the treatment groups provide evidence of 
the positive effect of Potaba@ therapy on sur- 
vival and the importance of adequate dose and 
duration of treatment. 
Cox proportional hazards model results 
Although the life-table analyses have indi- 
cated the importance of age, race, sex, and 
KPAB treatment to the survival of scleroderma 
patients, these analyses were confounded by the 
heterogeneity of subgroups with respect to other 
factors affecting survival such as age or organ 
system involvement at the onset of treatment. 
The use of the Cox proportional hazards model 
permits the comparison of subgroups, and in 
particular treatment groups, adjusting for other 
factors known to affect survival. 
However, it should be recognized at the out- 
set that caution must be exercised in interpreting 
the results of the Cox analyses. There are a 
number of problems inherent in the application 
of the Cox model to a retrospective study such 
as this. Ideally, the Cox model will estimate the 
separate effect of treatment while controlling for 
patient demographics and health status at the 
date of entry. On the date of entry in a prospec- 
tive clinical trial, patients can be evaluated for 
all relevant health characteristics, randomly as- 
signed to treatment groups, and therapy ini- 
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tiated. The date of entry (the time the survival 
clock begins), the assessement of initial patient 
health status, and the beginning of treatment 
are synchronous. In a retrospective study the 
data do not conform to the ideal clinical trial. 
In the present study patients were not randomly 
assigned to treatment groups nor was there a 
systematic application of clinical tests. There 
were some patients for whom the clinical infor- 
mation necessary to assess their health status 
was simply not available. Moreover, patients 
did not necessarily begin treatment at any sys- 
tematic time in the course of their disease. 
However, first University Hospital visit did con- 
stitute the date on which a majority of patients 
received an extensive clinical evaluation and 
began treatment. 
First, results of the Cox model survival anal- 
ysis controlling only for demographic factors 
and treatment are given in Table 4. Like the life- 
table analyses, the Cox model results reported in 
Table 4 include all 390 patients. For this anal- 
ysis, which includes only demographic covar- 
iates, date of entry is also the date of diagnosis. 
Patients are allocated into the treatment groups 
(either adequate or inadequate) if they received 
KPAB at some time in the course of their 
disease. The analysis retains a covariate identi- 
fying the inadequately treated group to insure 
that no bias can result from including these 
patients as never treated and to demonstrate 
whether their survivorship dilfers from the never 
treated group. All covariates in the analysis 
except age are dichotomous with values zero 
and one where the value one for the variable 
indicates the presence of the covariate (e.g. race 
is white, sex is male, or received KPAB treat- 
ment). Age is measured in years of age at 
diagnosis and enters linearly into the model. 
There was no evidence that a quadratic term in 
age contributed substantially to the model. 
The results in Table 4 are consistent with the 
life-table analyses. Age remains an important 
determinant of survival with risk increasing 4% 
for each year of age at entry (p < 0.001). This 
analysis indicates the importance of gender in 
survival. Whereas the poor prognosis for males 
did not attain statistical significance at the 5% 
level in the life-table analysis, this model shows 
an increased risk of 60% for males over females 
and the difference attains significance (p = 
0.03). Prolonged life (a negative coefficient im- 
plying a lower hazard rate) is associated with 
whites relative to blacks and adequately sand 
inadequately treated patients relative to the 
never treated group. In this specification of the 
model whites show lower risk but again the 
difference does not attain significance at the 5% 
level. With respect to treatment these results 
con&m the conclusions reached in the life-table 
analysis on the importance of dose and duration 
of KPAB treatment. The adequately treated 
group shows a hazard rate 5 1% lower than the 
never treated group with the difference being 
highly sign&ant (p = 0.0004). The inade- 
quately treated group, on the other hand, shows 
a lower hazard rate relative to the never treated 
with KPAB group and, as in the life-table 
analysis, the difference is not sign&ant. 
The Cox model was next extended to include, 
in addition to age, sex, race, and treatment with 
KPAB, seven indicators of health status or 
organ system involvement at date of entry. As 
noted above, patients had not been clinically 
evaluated nor had treatment been initiated at 
any systematic time in the course of their dis- 
ease. However, first University Hospital visit 
did constitute the date on which the majority of 
patients were extensively evaluated. Moreover, 
KPAB treatment was initiated within 3 months 
‘of that visit for 121 of 2 19 adequately treated 
patients. Thus, tirst University Hospital visit 
was taken as the date on which potential follow- 
up began. Because the Cox analysis corrects for 
differences in health status at date of entry, the 
actual date of entry could not precede either the 
initial clinical assessment or, for the adequately 
treated patients, the date of initial treatment. 
Should the date of entry into the Cox analysis 
have preceded the date of first treatment, then 
survival time prior to the beginning of therapy 
would be inappropriately atttributed to a poten- 
Table 4. Survival analysis using Cox proportional-hazard model 
Standard 
Variable Coefficient error p-value Exp. (coefiicient) 
Age 
Male 
:: 0.006 <O.OlNl 1.04 
-0:51 
0.21 0.03 1.60 
white 0.27 0.08 0.60 
Inadequate KPAB treatment -0.16 0.26 0.53 0.85 
Adequate KPAB treatment -0.72 0.20 0.0004 0.49 
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tial treatment effect. Survival for the extended 
model was, therefore, defined as follows: for all 
treatment groups survival time prior to first 
University Hospital visit was excluded from 
the analysis. For the groups inadequately and 
never treated with KPAB, date of entry was 
the first occurrence of a complete clinical assess- 
ment at University Hospital. The adequately 
treated group was similarly defined; however, 
in addition, the survival clock did not 
begin until adequate KPAB treatment had been 
initiated. 
It is important to note that in some instances 
KPAB was often prescribed at one time but for 
various reasons adequate treatment did not 
begin for months or in a few cases, years later. 
For the adequately treated patients the date of 
first treatment was defined as the date that 
adequate treatment began regardless of when 
KPAB was prescribed in the past or how long 
the patient was inadequately treated before be- 
coming adequately treated. All survival time 
subsequent to adequate treatment with KPAB 
was considered survival time under treatment 
even if treatment was discontinued at some 
future time. 
Not all 390 patients could be included in the 
Cox analysis. First, patients were excluded who 
lacked a complete set of clinical data on a single 
visit or admission to University Hospital. Sec- 
ond, patients with short survival times consti- 
tuted a potential source of bias since they were 
effectively precluded from receiving adequate 
treatment. Thus, patients were excluded if death 
or loss to follow-up occurred within 3 months 
of their first University Hospital visit. The fol- 
lowing criteria define the sample population for 
the Cox analysis which included the clinical 
covariates: (1) patients were included in the 
sample who had completed tests for the desig- 
nated indicators (Table 5) within a 2-month 
span of time of a single visit to University 
Hospital; and (2) patients were included who 
were followed at least 3 months after admission 
to University Hospital. 
There were 294 of the 390 patients who had 
adequate clinical information and duration of 
follow-up to be included in the sample. Seventy- 
six patients were excluded because they never 
had complete clinical data on a single visit. An 
additional 20 were excluded because they either 
died or were lost to follow-up within 3 months 
of the first University Hospital visit. First Uni- 
versity Hospital visit was the date of entry for 
215 of the 294 patients, leaving 79 for whom the 
necessary data were obtained at subsequent 
Table 5. Clinical characteristics at date of entry and treatment distribution of 294 
patient with complete clinical data 
KPAB treatment 
Percent of patients in KPAB 
treatment group with indicated 
Total sample variable 
Number Percent Adequate Inadequate Never 
Adequate 179 60.9 - - - 
Inadequate 41 13.9 - - 
Never 74 25.2 - - - 
Demographics 

































85.9 84.1 90.2 87.5 
23.5 22.3 29.3 23.0 
79.9 80.4 80.5 78.4 
24.5 17.3 26.8 40.5 
4.8 1.7 4.9 12.2 
11.6 10.6 7.3 16.2 
20.4 15.7 24.4 29.7 
27.9 25.7 29.3 32.4 
51.7 58.7 46.3 37.9 
*The sample size for Raynaud’s phenomenon was 270 (24 of the 294 were missing 
values). Raynaud’s phenomenon was excluded from the Cox analysis for masons 
given in the text. 
i-Indicates the difference among treatment groups is significant at the 0.05 level. 
f Standard deviation in parentheses. 
Retrospective Studies in Scleroderma 201 
visits. There were 104 deaths, leaving 239 cases 
either lost to follow-up or alive at the end of the 
study. 
It is important to note that there were 79 
cases who were treated prior to the date of entry 
either because they were already under treat- 
ment when they came to the University Hospital 
[38] or they were begun on treatment but did not 
have all the clinical data necessary for inclusion 
in the Cox extended model until a subsequent 
visit [41]. These 79 patients were treated for an 
average of 2.5 years before the date of entry into 
the Cox analysis. This time of co&dent treat- 
ment and survival which preceded date of entry 
was excluded in order to meet the criteria of the 
Cox model. 
With the exception of skin involvement and 
age, all covariates in the model are dichotomous 
variables with the values of zero and one, where 
one indicates that the patient has the associated 
clinical involvement, is white or female, or is 
adequately or inadequately treated. Age defined 
as age in years at date of entry, enters linearly 
into the analysis. The covariate for skin 
involvement enters into the analysis linearly 
taking on the values one, two, and three. The 
value one indicates minimum or mild skin in- 
volvement, two indicates moderate, and the 
value three indicates marked or severe in- 
volvement [l]. A graphical evaluation of the 
proportionality assumption of the Cox model 
indicated this was an appropriate way to model 
skin involvement. A similar evaluation for the 
treatment groups revealed no evidence of non- 
proportionality. 
Table 5 summarizes the clinical character- 
istics by treatment group of the sample popu- 
lation used in the Cox analysis. The findings 
given in Table 5 indicate that patients were not 
randomly assigned to treatment groups. Pa- 
tients with higher degress of skin involvement 
were more likely to receive KPAB (p < 0.01); 
while those with renal involvement or hyper- 
tension were less likely to receive this medica- 
tion (p < 0.01 for both). There are a number of 
additional statistical correlations among the co- 
variates worth noting; (1) Raynaud’s phenom- 
enon is positively correlated with esophageal 
involvement (p < 0.01). (2) Pulmonary in- 
volvement is positively correlated with heart 
involvement -(p < 0.01) and hypertension 
(p < 0.01). (3) Heart involvement is, in addi- 
tion, positively correlated with hypertension 
(p < O.Ol), and renal involvement (p < 0.01). 
Despite the non-random assignment of cases, 
the Cox model will adjust for the differences 
among treatment groups at the date of entry. 
Table 6 shows the results of the Cox 
proportional-hazards model adjusting for de- 
mographics, clinical characteristics, and treat- 
ment. The analysis reported here excludes the 
covariate for Raynaud’s phenomenon because 
preliminary analysis consistently showed Ray- 
naud’s to be an insignificant prognostic indi- 
cator. By eliminating Raynaud’s the model 
gains a degree of freedom and additional cases 
could be added to the sample because the 
criteria for inclusion into the sample required 
complete data for six clinical covariates instead 
of seven. 
As in the previous analysis, Table 6 shows 
prolonged life is associated with whites relative 
to non-whites, and inadequate and adequate 
KPAB treatment relative to the never treated 
Table 6. Cox proportional-hazard model results 
Covariate 
Standard 
















0.014 0.009 0.10 1.01 
0.416 0.25 0.11 1.52 
- 0.203 0.33 0.55 0.82 
0.449 0.29 0.10 1.57 
0.466 0.24 0.06 1.59 
0.693 0.26 0.01 2.00 
0.470 0.25 0.06 1.60 
0.476 0.38 0.23 1.61 
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group. The influence of race and of inadequate 
treatment on survival was in the same direction 
as were the results in the life-table analysis but 
did not reach statistical significance. This model 
indicates that adequate treatment results in a 
38% reduction in the hazard rate but the 
coefficient is only marginally significant 
(p = 0.08). 
A relatively poor prognosis is associated with 
all of the clinical factors. Table 6 shows the 
worst prognosis is for those patients with heart 
involvement with a hazard rate 100% higher 
than for those with normal heart function 
(p = 0.01). The extent of skin involvement is 
also a powerful prognostic indicator of survival 
having the greatest explanatory power in the 
model (p = 0.002). The more extensive the skin 
involvement at date of entry, the more reduced 
is survivorship. The results indicate that patients 
with marked involvement have hazard rates 
54% higher than those with moderate in- 
volvement. Similarly, because the model re- 
stricts the difference in hazard rates between the 
groups to be proportionally constant, the haz- 
ard rate for those with moderate skin in- 
volvement is 54% higher than for the group 
with minimum or mild involvement. 
Pulmonary fibrosis increases risk by 59% 
(p = 0.06). Hypertension leads to a 60% in- 
creased hazard rate over those without hyper- 
tension (p = 0.06). Renal involvement shows an 
increased risk of 61% but was not significant. 
However, it may be noted from Table 5 that 
there were only 14 cases who met the criteria for 
renal involvement in this sample. 
The Cox analysis was repeated using the 
stepwise regression method. In contrast to the 
results in Table 6 which weighed the relative 
contribution of each covariate, the stepwise 
method indicates the group of variables which 
has the greatest prognostic power, in the order 
of that power, to explain the variation in sur- 
vival times, This method showed that the pres- 
ence of hypertension in scleroderma patients 
had the strongest prognostic power (p < 0.001). 
Hypertension was followed by cardiac in- 
volvement (p = 0.001) pulmonary involvement 
(p = 0.009) extent of skin involvement 
(p = 0.014), and renal involvement (p = 0.06). 
In addition, the Cox analysis reveals that 
patients with renal involvement or hypertension 
are relatively high risk patients. Because these 
patients were also less likely to receive KPAB 
(especially those with renal involvement), the 
patient population was separated into two sub- 
groups, those with renal involvement and/or 
hypertension, and those without. A Cox anal- 
ysis was then performed on each group sepa- 
rately. The results showed a differential effect of 
KPAB on the two groups. In the low risk group, 
i.e. those without renal involvement or hyper- 
tension, adequate treatment resulted in a lower 
hazard rate (55% lower than for the never 
treated group) and a higher level of significance 
(p = 0.048) compared to the total population 
sample. There was no treatment effect in the 
high risk group. The results suggest that treat- 
ment prevents or delays progression of some 
aspects of the disease and thereby prolongs 
survival. However, once renal involvement or 
hypertension are present the patients face a poor 
prognosis, notwithstanding treatment with 
KPAB. 
Finally, with regard to the present study, 
there was no selection as to which patients 
charts were extracted: availability of records 
was the determining factor. That this process 
itself may have introduced bias regarding treat- 
ment results was considered. Table 7 sum- 
marizes the incident and prevalent cases by 
KPAB treatment groups. Incident cases were 
defined as those patients whose diagnosis of 
scleroderma was made less than 1 year from 
onset of symptoms. Table 7 shows that the 
percentage of incident and of prevalent cases are 
approximately equal across treatment groups. 
Table 7. Incident* and prevalent cases by treatment groups 




Adequate Inadequate Never 
3907 219 55 116 
137 
(31!i%) (37.$/k) 
244 37 71 
(63.6%) (68.5%) (62.8%) 
*Incident cases diagnosed scleroderma within 1 year after first 
symptom/sign. 
tNine cases are missing date for first symptom/sign. 
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The mean duration of symptoms to start of 
treatment for patients adequately treated with 
KPAB was 5.7 years (range O-35 yr). For those 
iniidequately treated or never treated the mean 
duration of symptoms ,to first University Hospi- 
tal. visit was 8.3 years (range O-30 yr) and 4.8 
years (range O-45 yr), respectively. The 
differences in the means were not statistically 
significant. Both of these results indicate that 
there was no bias introduced on the basis of 
differential assignment of patients with long 
duration from onset of symptoms. 
DISCUSSION 
In the present study, several methods of anal- 
ysis were applied to assess the survival times for 
390 scleroderma patients who were seen at The 
University of Michigan Hospital over the period 
1948 to July 1980. Although some biases in the 
analyses still remain there is strong evidence of 
a KPAB effect on survival. Each of the analyses 
has indicated prolonged survival for sclero- 
derma patients adequately treated with potas- 
sium para-aminobenzoate relative to the 
inadequately and never treated groups. The 
analyses have also shown prolonged svrvival for 
the:eniire population relative to other studies of 
scleroderma patients. C.umulative survival rates 
for the entire group were 81.4% at 5 years, 
77.i% at 7 years, and 69.4% at 10 years. 
Medsger et al. [3] performed life-table analysis 
of survivorship for 309 scleroderma patients 
and found the cumulative survival to be 35% at 
seveq years. In a separate study of 358 sclero- 
derma male patients in veterans hospitals, Me- 
dsger and Masi [4] found the cumulative sur- 
vival rate to be 35 percent at seven years. The 
largest group of patients for whom survival 
rates are available is that of Tuffanelli and 
Winkelman [lo] who found 5-year survival for 
70.3% and lo-year survival for 58.9% of pa- 
tients traced. 
Several factors .may have contributed to the 
prolonged survival of our patients. First, the 
survival differences may be due in part to 
differences in definition of entry into the study. 
Like Bennett et al. [2], our life-table analyses 
define entry into study as the date of initial 
scl&derma diagnosis. 
Second, the fact that our patients were diag- 
nosed’ younger on average than other large 
reported series, with the exception of the study 
by TuEanelli and Winkelman may have also 
contributed to the difference in survivorship. 
The mean age at entry for Bennett et al. was 
46.2 years, 40.3 for TufFanelli and Winkehnan 
[5], while for the present study the mean age of 
entry was 42.5 years. 
Finally, KPAB therapy has also contributed 
to higher survival rates in the present study. If 
we compare the cumulative survival rates of the 
never treated group,with those in the literature 
the similarity is much greater. This is particu- 
larly true when we compare the never treated 
with KPAB group to the study of Bennett et al. 
[2]. The 5-year and lo-year survival rates for the 
group never treated with KPAB are 69.8 and 
56.6%, respectively, compared to 73 and 50%, 
reported by Bennett et al. When the group 
treated with KPAB is separately analyzed (Ta- 
ble 3), 5-year survival is 88.5% and IO-year 
survival is 76.6% for adequately treated pa- 
tients. The difference in survival for patients 
adequately treated with KPAB and those who 
have at no time received this medication was 
statistically significant (p < 0.01). 
The effect of KPAB on prolongation of sur- 
vival was also evident in comparisons of ob- 
served to expected mortality for these patients. 
For example, the excess mortality rate was 23.8 
for those adequately treated with KPAB as 
contrasted to 58.26 for those who never received 
it. 
The present study confirms the results in 
previous studies with respect to the association 
between age and sex and survival. In our life- 
table analysis, the subgroup where age is greater 
than 40 ai diagnosis exhibited significantly de- 
creased survivorship compared to those under 
40 as was found by Bennett et al. [2]. Similarly, 
males had a significantly poorer prognosis for 
survival compared to that of females. 
Medsger et al. [J] noted decreased survival for 
blacks in the early years of their study, but did 
not find the race difference significant over the 
entire period of follow-up. Similarly our non- 
white patients showed decreased survival rela- 
tive to their white counterparts, but the 
difference was not statistically significant at the 
5% level. 
Because of the important implications of the 
foregoing findings with respect to prolongation 
of survival consequent to KPAB therapy, it was 
deemed important to utilize the Cox 
proportiooal-hazards model in an effort to as- 
sess the relative importance of various covar- 
iates in determining survival. First, when the 
Cox model was applied to the entire population 
measuring survival from the date of diagnosis 
and anly adjusting for demographics and treat- 
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ment, the results were statistically significant for 
age (p < O.OOl), gender (p = 0.03), and ade- 
quate treatment with KPAB (p = 0.002) while 
the effect of race was only marginally significant 
(p = 0.06). The Cox model was next applied to 
the analysis of six clinical variables in addition 
to age, race, gender, and treatment (KPAB). It 
should be kept in mind that the Cox model is 
suited to prospective studies and that its appli- 
cation to this retrospective analysis required a 
number of adjustments which may well have 
biased the results. In particular, the correlations 
between treatment and the clinical variables for 
renal, hypertension, and skin involvement indi- 
cate that patients were not randomly assigned to 
treatment groups. Several additional points 
need to be emphasized. First, it should be noted 
with respect to the negative correlation for 
KPAB and renal involvement, that since the 
drug is excreted via the kidneys it is generally 
not administered to patients with significant 
renal involvement. Second, patients with higher 
degrees of skin involvement were more likely to 
receive KPAB. Third, applying a model that 
adjusts for baseline clinical involvement re- 
quired the exclusion of survival time prior to 
the patient’s complete clinical evaluation. A 
significant amount of survival time for patients 
on adequate treatment was thereby excluded. 
There were of course a number of other cor- 
relations among the clinical covariates. All of 
these variables and correlations are to be 
separately examined in detail and will therefore 
not be discussed here. 
Despite the difficulties and the inherent prob- 
lems of retrospective studies there were some 
interesting results produced by this analysis. 
Pulmonary (p = 0.06), heart (p = O.Ol), and 
extent of skin involvement (p = 0.002) prove to 
be important prognostic indicators of survival. 
Adequate treatment with KPAB still indicates 
prolonged survival with marginal significance. 
Age, gender, and race are not significant factors 
in determining survival as found by this method. 
Moreover, application of the stepwise re- 
gression method with the Cox analysis altered 
the order of explanatory power of the prognos- 
tic variables. 
The Cox analysis finding that extent of skin 
involvement per se is a significant prognostic 
variable raises the possibility that extent of skin 
involvement may reflect a magnitude of meta- 
bolic stress or derangement not previously ap- 
preciated. The survival data presented herein 
suggest that treatment with KPAB which was 
initially directed toward softening of involved 
skin is indeed associated with improved sur- 
vival. 
The prolongation of life associated with 
KPAB therapy can be linked to its more direct 
effect on organ system involvement. The results 
suggest that treatment prevents or delays the 
progress of some aspects of the disease. The 
patient population was separated into two 
groups, those with renal involvement and/or 
hypertension and those without. A separate Cox 
analysis performed on each group revealed a 
differential treatment effect. The effect of KPAB 
therapy was significant in the low risk group 
while treatment was ineffective for those who 
had already developed renal involvement and/or 
hypertension. 
In a separate paper [l] KPAB has been shown 
to soften thickened, fibrotic skin changes in 
patients with scleroderma. The effect of KPAB 
on skin of scleroderma patients however, may 
be only one aspect of its improvement on sur- 
vival. Analyses of pulmonary findings and 
changes in the course of follow-up of patients in 
this study group have shown a significant effect 
of KPAB therapy on vital capacity and a lesser 
though favorable effect on carbon monoxide 
diffusing capacity [I 11. 
It is of relevant interest to note a. recent 
publication by Steen et al. [12], which reported 
on the treatment of scleroderma with 
D-penicillamine (DPA). These authors com- 
pared 73 patients treated with D-penicillamine 
for a minimum of 6-months with 45 patients 
who did not receive this drug. Survival by the 
life-table method was increased for the treated 
group (88 vs 66%, p c 0.05). The average age 
for the DPA treated patients was 45.3 years 
while that of the comparison group was 48 
years. Patients who had the disease for more 
than 3 years were excluded from their study as 
they were considered to have “irreversible 
fibrosis of skin and viscera”. Since we had made 
no such exclusions in the present study, our 
population was re-analyzed and showed that 65 
of our 390 cases had been diagnosed as having 
scleroderma for more than 3 years on the first 
visit to University Hospital. When these 65 
patients were excluded from the life-table anal- 
ysis there was a small increase in the significance 
for KPAB treatment. 
The Cox model was also used to investigate 
whether the time interval in years from diagno- 
sis to the first University Hospital admission or 
visit had any bearing on the patient’s survival. 
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The Cox proportional-hazards model showed festations of Scleroderma”, after prior review and approva 
that, adjusting for the covariates in Table 6, the by the Institutional Review Board of The University of 
interval before hospital admission did not 
Michigan Medical Center. 
influence survival (less than 1% reduction in 
risk, p = 0.92). Clearly, acceptance into treat- 
ment programs should not be limited arbitrarily 
on the basis of duration of scleroderma. 
Finally, it may be noted that the chronic use 
of large doses of KPAB in scleroderma was 
based on the empirical observation of an associ- 
ated skin softening effect. The present study 
yields evidence that skin as well as internal 
organ-system involvement have prognostic 
significance. In addition, these retrospective 
analyses indicate an improved survival from 
treatment with KPAB. It is believed that the 
findings in these and related analyses of this 
group of 390 patients will help to identify areas 
upon which to focus future clinical studies of 
scleroderma. 
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